Cystic Fibrosis Clinical Trial
Official title:
A Prospective Study to Evaluate Biological and Clinical Effects of Significantly Corrected CFTR Function (the PROMISE Pediatric 6 to 11 Years Old Study)
Verified date | December 2023 |
Source | Seattle Children's Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
This is a prospective, multi-center observational study. The study is designed to measure the clinical effectiveness of elexacaftor, tezacaftor and ivacaftor (ETI) triple combination therapy in children (6-11 years of old) with one or more copies of the F508del mutation, study the effects of ETI across a number of CF disease manifestations, and collect specimens for future research. Subjects in the study will have one "before ETI" visit within 30 days before initiation of the therapy and five "after ETI" visits over a 24-month follow-up period. Participants who have participated in the original PROMISE Pediatric Sub-Study have the option of participating in a long-term extension with annual visits performed at the 36- and 48-month timepoints. The durability of the clinical and biological changes in the PROMISE Pediatric Sub-Study can be assessed with extended follow-up, which would enable the sub-studies to consider potential clinical consequences of the biological or physiological effects being studied. This work will help to inform long term prognosis and feasibility of certain clinical trials outcomes for interventional studies and may be useful when considering research priorities in drug development. The duration of participation for each subject is 24 months (with an additional 24 months if participants agree to the optional long-term extension). NOTE: FDA has granted approval for elexacaftor, tezacaftor and ivacaftor in the 6-11 age group.
Status | Active, not recruiting |
Enrollment | 180 |
Est. completion date | December 19, 2025 |
Est. primary completion date | December 19, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 11 Years |
Eligibility | Inclusion Criteria: 1. Written parental informed consent and assent obtained from subject and the subject's legal guardian. 2. Be willing and able to adhere to the study visit schedule and other protocol requirements. 3. All genders 6-11 years old on Day 1. 4. Diagnosis of CF. 5. CFTR mutations consistent with the FDA labeled indication for the ETI. 6. Physician intent to prescribe the ETI. 7. Able to attempt the testing and procedures required for this study, as judged by the investigator. 8. Enrolled in the Cystic Fibrosis Foundation Patient Registry. 9. Clinically stable with no significant changes in health status within the 14 days prior to Visit 1 (and inclusive of Visit 1). Exclusion Criteria: 1. Has any other condition that, in the opinion of the Site Investigator/designee, would preclude informed consent or assent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives. 2. Use of any ETI within the 180 days prior to Visit 1. 3. Any acute use of antibiotics (oral, inhaled or IV) or acute use of systemic corticosteroids within the 14 days prior to Visit 1 (inclusive of Visit 1) for lower respiratory tract symptoms. 4. Initiation of any new chronic therapy (e.g., ibuprofen, Pulmozyme®, hypertonic saline, azithromycin, inhaled tobramycin, Cayston®, Kalydeco, Orkambi®, Symdeko®) within the 4 weeks prior to Visit 1 (inclusive of Visit 1). 5. Use of an investigational agent within the 28 days prior to Visit 1. 6. Use of chronic oral corticosteroids (equivalent to 10 mg. or more per day of prednisone) within the 28 days prior to Visit 1. 7. Treatment for nontuberculous mycobacterial (NTM) infection, consisting of = two antibiotics (oral, IV, and/or inhaled) within the 28 days prior to Visit 1. 8. History of lung or liver transplantation,or listing for organ transplantation. |
Country | Name | City | State |
---|---|---|---|
United States | Children's Hospital Colorado | Aurora | Colorado |
United States | John Hopkins University | Baltimore | Maryland |
United States | University of Alabama at Birmingham | Birmingham | Alabama |
United States | Boston Children's Hospital, Brigham & Women's Hospital | Boston | Massachusetts |
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | Ann & Robert H. Lurie Children's Hospital of Chicago | Chicago | Illinois |
United States | Cincinnati Children's Hospital Medical Center | Cincinnati | Ohio |
United States | Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center | Cleveland | Ohio |
United States | Baylor College of Medicine | Houston | Texas |
United States | Riley Hospital for Children | Indianapolis | Indiana |
United States | University of Iowa | Iowa City | Iowa |
United States | Children's Mercy Kansas City | Kansas City | Missouri |
United States | University of Wisconsin | Madison | Wisconsin |
United States | Children's Hospital of Wisconsin | Milwaukee | Wisconsin |
United States | The Minnesota Cystic Fibrosis Center | Minneapolis | Minnesota |
United States | Stanford University Medical Center | Palo Alto | California |
United States | Oregon Health Sciences University | Portland | Oregon |
United States | Virginia Commonwealth University | Richmond | Virginia |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Seattle Children's Hospital | Seattle | Washington |
Lead Sponsor | Collaborator |
---|---|
Nicole Hamblett | Cystic Fibrosis Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sweat Chloride at 6 months | Change in sweat chloride from Baseline to 6 months. | 6 months | |
Primary | Sweat Chloride at 24 months | Change sweat chloride from Baseline to 24 months. | 24 months | |
Primary | Forced expiratory volume at one second (FEV1) at 6 months | Change in FEV1 from Baseline to 6 months. | 6 months | |
Primary | Forced expiratory volume at one second (FEV1) at 24 months | Change in FEV1 from Baseline to 24 months. | 24 months | |
Primary | Lung Clearance Index (LCI) at 6 months | Change Lung Clearance Index (LCI) from baseline to 6 months. | 6 months | |
Primary | Lung Clearance Index (LCI) at 24 months | Change Lung Clearance Index (LCI) from baseline to 24 months. | 24 months | |
Secondary | Weight at 6 Months | Change in weight from Baseline to 6 months. | 6 months | |
Secondary | Weight at 24 Months | Change in weight from Baseline to 24 months. | 24 months | |
Secondary | BMI at 6 Months | Change in BMI from Baseline to 6 months. | 6 months | |
Secondary | BMI at 24 Months | Change in BMI from Baseline to 24 months. | 24 months | |
Secondary | Cystic Fibrosis Questionnaire Revised (CFQ-R) at 6 Months | Change in CFQ-R (respiratory domain) from Baseline to 6 months. | 6 months | |
Secondary | Cystic Fibrosis Questionnaire Revised (CFQ-R) at 24 Months | Change in CFQ-R (respiratory domain) from Baseline to 24 months. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |